The NTB Forecast redefines pharmaceutical launch planning by focusing on new patient acquisition rather than broad market size, addressing a key flaw in traditional models that overestimate share and misalign strategies. By isolating the dynamic market and tracking uptake curves, it delivers over 90% accuracy for launches and 95% for in-market brands, enabling better resource allocation and sales alignment. IQVIA’s methodology, enhanced by analogues, epidemiology data, and physician insights, ensures agility during the critical first six months of launch. Case studies show forecasts achieving up to 98% accuracy, helping pharma optimize launches and long-term brand performance.

Join for free to read